Free Trial
NASDAQ:EDSA

Edesa Biotech Q4 2024 Earnings Results & Report

Edesa Biotech logo
$2.86 -0.08 (-2.55%)
As of 03:47 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Edesa Biotech beat analyst earnings expectations in its Q4 2024 results, released December 13, 2024. The company reported EPS of -$0.29 versus the -$0.54 consensus estimate.

Earnings Announcement Details

Quarter
Q4 2024
Time
After Market Closes

Edesa Biotech EPS Results

Actual EPS
-$0.29
Consensus EPS
-$0.54
Beat/Miss
Beat by +$0.25
One Year Ago EPS
N/A
EPS Beat Rate
3 of last 8 quarters

Edesa Biotech Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

Edesa Biotech's next earnings date is estimated for Friday, December 11, 2026, based on past reporting schedules.

Conference Call Resources

Edesa Biotech Q4 2024 Earnings FAQ

Edesa Biotech (NASDAQ:EDSA) reported earnings of -$0.29 per share for Q4 2024, beating the consensus estimate of -$0.54. The report was announced on Friday, December 13, 2024.

Edesa Biotech's next earnings date is estimated for Friday, December 11, 2026. MarketBeat tracks confirmed and estimated earnings dates for Edesa Biotech on the company's earnings history page.

Edesa Biotech Earnings Headlines

Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.tc pixel
Edesa Biotech prices $25M equity offering
See More Edesa Biotech Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Edesa Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Edesa Biotech and other key companies, straight to your email.

About Edesa Biotech

Edesa Biotech (NASDAQ:EDSA) is a clinical-stage biopharmaceutical company focused on developing therapeutics for inflammatory and immune-mediated diseases. The company does not have any marketed products and concentrates on advancing investigational treatments through clinical development and regulatory evaluation.

Edesa’s lead program has been EB01, a topical therapy being developed for chronic hand eczema, a painful inflammatory skin condition that can significantly affect patients’ daily activities. The company has also evaluated EB05, an antibody-based treatment candidate intended to address excessive inflammation associated with acute respiratory distress syndrome and other serious conditions. The status of individual programs may change as clinical and regulatory work progresses.

Edesa is headquartered in Markham, Ontario, Canada, and has conducted development activities in Canada and the United States. The company was founded to pursue therapies for diseases with limited treatment options and has worked with research, clinical, and regulatory partners in advancing its programs. Par Nijhawan has served as the company’s chief executive officer.

View Edesa Biotech Profile